PROFILE |
 |
Like a menacing creature from outer space, Photoelectron wants to irradiate you from the inside out. The company makes the Photon Radiosurgery System (PRS), a device for removing tumors. The PRS delivers a high dose of radiation through a needle-like probe that emits precisely controlled, low-energy X-rays from its tip, irradiating a tumor from the inside out. Applications include brain, breast, colorectal, and skin tumors. Photoelectron also plans to use the PRS to treat age-related macular degeneration, a leading cause of blindness. With German firm Carl Zeiss, the company developed the INTRABEAM radiotherapy system for use with the PRS. Chairman Peter Nomikos owns nearly half of Photoelectron.
COMPETITION |
 |
Matrix Pharmaceutical, Inc. (MATX)
QLT Inc. (QLTI)
Theragenics Corporation (TGX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.40
1-Yr. Sales Growth: 180.0%
Employees: 30
Revenue per employee: $46,666.67
KEY PEOPLE |
 |
Euan S Thomson
CEO
Timothy W. Baker
CFO
CONTACT INFO |
 |
5 Forbes Rd., Ste. 2
Lexington, MA 02421
US
Phone: 781-861-2069
Fax: 781-259-0482
Online: Web Site
|